Media room >
Scleroderma Manitoba’s summer funding campaign
June was scleroderma awareness month throughout the world. It is a privileged time to inform and raise the general public’s awareness of the existence of this little-known and orphan disease and the capital importance of research to find a curative treatment. This year, Scleroderma Manitoba launched the “Demystify scleroderma” campaign. Share in large numbers!
OFEV® (nintedanib) now available in Canada for progressive fibrotic interstitial lung diseases (PF-ILD)
BURLINGTON, ON, May 25, 2020 /CNW/ – Boehringer Ingelheim (Canada) Ltd. announced today that OFEV® (nintedanib) is authorized for sale by Health Canada for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD). Interstitial lung diseases (ILDs) encompass more than 200 disorders that can lead to irreversible scarring of lung tissue, negatively impacting lung function. An estimated 18 to 32 per cent of patients with ILDs will develop a progressive fibrosing course of the disease. This new indication now makes OFEV® available for patients with progressive fibrosing ILDs in which lung fibrosis continues to worsen.